Life Tech has gained global distribution rights to the system, which is a compact multiplex analyzer that rapidly detects 50 different analytes simultaneously on a single sample.
Garvan Institute will evaluate HealthLinx's prostate cancer biomarkers under one deal, while CPC Clinical Research will liaise with the FDA for HealthLinx's OvPlex test under a separate agreement.
RBM acquired biomarker-related IP for Alzheimer's disease and other central nervous system conditions.
Consumables sales were up 53 percent during the quarter to an all-time high of $15 million.
The firm has received pre-IDE evaluations from the FDA for BreastGeneDx and is currently looking for partners to help it during the next stage of assay validation.
The Prevail patient registry will be used to analyze primary care ambulatory practices for risk factor management of patients who have a high risk of converting to type 2 diabetes.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.